Request Demo

Last update 28 Feb 2026

Iloperidone

Last update 28 Feb 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1- piperidinyl]propoxy]-3-methoxyphenyl]ethanone, 4'-(3-(4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidino)propoxy)-3'-methoxyacetophenone, Fanaptum

+ [10]

Target

5-HT2A receptor x D2 receptor

Action

antagonists

Mechanism

5-HT2A receptor antagonists(Serotonin 2a (5-HT2a) receptor antagonists), D2 receptor antagonists(Dopamine D2 receptor antagonists)

Therapeutic Areas

Other DiseasesNervous System Diseases

Active Indication

Bipolar I disorderManiaSchizophrenia

Inactive Indication

Acute schizophreniaIrritable MoodOsteoarthropathy, Primary Hypertrophic+ [3]

Originator Organization

Novartis Pharma AG

Active Organization

Vanda Pharmaceuticals, Inc.

Novartis AG

Probiomed SA de CV

Inactive Organization

Novartis Pharmaceuticals Corp.

License Organization

Novartis AG

Vanda Pharmaceuticals, Inc.Aventis SA

+ [1]

Drug Highest PhaseApproved

First Approval Date

United States (06 May 2009),

Schizophrenia

Regulation-

Structure/Sequence

Molecular FormulaC24H27FN2O4

InChIKeyXMXHEBAFVSFQEX-UHFFFAOYSA-N

CAS Registry133454-47-4

Clinical Trials associated with Iloperidone

NCT07090161

/ RecruitingPhase 2

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Iloperidone for the Treatment of Participants with Uncontrolled Hypertension

Start Date15 Sep 2025

Sponsor / Collaborator

Vanda Pharmaceuticals, Inc.

NCT06961968

/ RecruitingPhase 3

A Multicenter, Double-Blind, Randomized Withdrawal Study in Patients With Schizophrenia Receiving Either Iloperidone Long-Acting Injection (LAI) or Placebo Injection

The purpose of this research is to evaluate the efficacy of dosing iloperidone long-acting injection (LAI) compared to placebo in preventing the exacerbation of symptoms in patients with schizophrenia.

Start Date14 May 2025

Sponsor / Collaborator

Vanda Pharmaceuticals, Inc.

NCT06494397

/ CompletedPhase 1

Crossover Bioequivalence Study of 12 mg VHX-896 and Iloperidone Tablets Under Steady-State Conditions

Study to compare the pharmacokinetics and pharmacodynamics of VHX-896 and iloperidone and evaluate the safety and tolerability of VHX-896 and iloperidone in patients with schizophrenia or bipolar I disorder under steady state conditions.

Start Date11 Jul 2024

Sponsor / Collaborator

Vanda Pharmaceuticals, Inc.

100 Clinical Results associated with Iloperidone

100 Translational Medicine associated with Iloperidone

100 Patents (Medical) associated with Iloperidone

318

Literatures (Medical) associated with Iloperidone

02 Nov 2025·Expert Opinion On Drug Safety

Drug-induced erectile dysfunction: a real-world pharmacovigilance study using the FDA adverse event reporting system database

Article

Author: Zhang, Rui ; Li, Dongxuan ; Du, Qian ; Zhu, Jun ; Wang, Yalan ; Dai, Liyang ; Liu, Songqing ; Zhang, Tongyan ; Wu, Fan

BACKGROUND:

The comprehensive quantitative and comparative risk data of drug-induced erectile dysfunction (ED) are still lacking, and this study aims to supplement this information.

RESEARCH DESIGN AND METHODS:

We reviewed all the ED reports in the FDA Adverse Event Reporting System (FAERS) database from 2004 to 2023 and summarized a potential ED culprit-drug list and its corresponding reporting frequency. The reporting odds ratio (ROR) method was used to conduct disproportionality analysis.

RESULTS:

A total of 20,098 ED reports were retrieved from the FAERS database, which recorded 734 different ED culprit-drugs, involving 74 drug classes. Finasteride was the drug with the highest reporting frequency, and urologicals was the drug class with the highest reporting frequency. In disproportionality analysis, 209 drugs with positive signals showed a close relationship with ED occurrence, among which finasteride was the drug with the highest signal strength. Among 209 drugs with positive signals, 27 were compound preparations, and the risk level of compound preparations was usually higher than their single active ingredient.

CONCLUSIONS:

Our study integrated quantitative and comparative ED risk data of 734 drugs by using the FAERS database, which can provide reference information for regulators, medical personnel, and others involved in drug management and use.

02 Nov 2025·CLINICAL TOXICOLOGY

QT interval prolongation in acute antipsychotic poisoning: systematic review and recommendations

Review

Author: Berling, Ingrid ; Wong, Anselm ; Ferrer Dufol, Ana Maria Alicia ; Mackenzie, Constance Alexa ; Yates, Christopher ; Hayes, Bryan D ; Isbister, Geoffrey K ; Hatten, Benjamin W ; Hoffman, Robert S ; Gosselin, Sophie ; Heyerdahl, Fridtjof ; Stanton, Matt ; Lonati, Davide ; Roberts, Darren M ; Hoegberg, Lotte C G ; Smith, Angela ; Othong, Rittirak ; Paasma, Raido

INTRODUCTION:

Antipsychotic medications are often associated with QT interval prolongation, which can lead to ventricular dysrhythmias, including torsade de pointes. However, unstable or significant dysrhythmic events are rare. Evidence-based recommendations on the assessment and management of poisoned patients at risk for QT interval prolongation are lacking. Current practice often involves costly and lengthy cardiac monitoring, leading to delayed disposition of the patient from emergency departments or prolonged monitoring times in other hospital units. To address this issue, the QT Interval Prolongation in Clinical Toxicology Workgroup was formed by the Clinical Toxicology Recommendations Collaborative to develop evidence-based recommendations for the management and treatment of QT interval prolongation in acute overdose patients. This article reports our findings on patients with antipsychotic poisoning.

METHODS:

A systematic review of the literature regarding QT interval prolongation in all acute overdoses was undertaken, and the evidence was summarized for antipsychotic medication overdose. Voting statements were drafted using a predetermined format for monitoring the QT interval and use of continuous cardiac monitoring. A two-round modified Delphi method was used to reach a consensus. The strength of consensus was measured using the disagreement index as defined by the RAND/UCLA Appropriateness Method.

RESULTS:

From the 327 articles that were included in the systematic review of QT interval prolongation in all acute overdoses, a total of 55 articles were relevant to antipsychotic medication-induced QT prolongation in acute overdose. Medications with more than three articles were reviewed individually for recommendations, whilst medications with less than three were grouped together for discussion as miscellaneous. Individual medication recommendations were made for amisulpride (15 articles), thioridazine (11 articles), ziprasidone (eight articles) and quetiapine (13 articles), whilst consensus statements based on limited data were made for acute ingestions of clozapine, haloperidol, iloperidone, pimozide, pipamperone, olanzapine and risperidone (14 articles in total). The electrocardiogram is suggested as a risk assessment tool for ingestion of all antipsychotic medication. We recommend continuous cardiac monitoring for patients ingesting more than amisulpride 2 g, thioridazine 1 g, and ziprasidone 3 g. We suggest continuous cardiac monitoring for the above-mentioned medications for lower dose ingestions as well as for ingestions of haloperidol, iloperidone, pimozide and pipamperone. We do not suggest continuous cardiac monitoring for acute clozapine and risperidone poisoning, and do not recommend continuous cardiac monitoring for the QT interval in acute olanzapine or quetiapine poisoning. The need for ongoing cardiac monitoring should be guided by an individual risk assessment considering the medication and dose ingested, the time since ingestion, as well as other factors such as heart rate or co-ingestions.

DISCUSSION:

The quality of evidence for the risk of QT interval prolongation and torsade de pointes is heterogeneous among different antipsychotics and inherently constrains the recommendations. Available data suggest that amisulpride, thioridazine and ziprasidone are associated with QT interval prolongation and torsade de pointes, while the risk is likely overstated for quetiapine, olanzapine and risperidone. Ongoing research is needed to improve management strategies for acute antipsychotic overdose-induced QT interval prolongation and dysrhythmias.

CONCLUSIONS:

The QT Interval Prolongation in Clinical Toxicology Workgroup recommends the use of screening electrocardiograms in all patients with acute antipsychotic medication overdose and cardiac monitoring in patients with at-risk overdoses from thioridazine, amisulpride, and ziprasidone. The QT Interval Prolongation in Clinical Toxicology Workgroup suggests the same approach for patients with overdoses of haloperidol, iloperidone, pipamperone and pimozide. The risk of torsade de pointes is likely overstated for acute antipsychotic medication overdose as a general class group, and concern should rather focus on a few specific medications.

01 Oct 2025·CNS DRUGS

Antipsychotic-Related Prolactin Changes: A Systematic Review and Dose–Response Meta-analysis

Review

Author: Wu, Hui ; Correll, Christoph U ; Leucht, Stefan ; Lin, Xiao ; Qin, Mengchang ; Siafis, Spyridon ; Schneider-Thoma, Johannes ; Tian, Jing

BACKGROUND:

Prolactin increase is a common and potentially problematic adverse event of antipsychotics. We aimed to discover the relationship between antipsychotic doses and changes in prolactin levels.

OBJECTIVE:

To examine the relationship between antipsychotic doses and changes in prolactin levels in adults with acutely exacerbated schizophrenia.

METHODS:

We searched the Cochrane Schizophrenia Group register (last search 26 July 2024) and previous reviews for fixed-dose, randomized controlled trials (RCTs) that investigated monotherapy of 21 antipsychotics in adults with acutely exacerbated schizophrenia. The primary outcome was mean prolactin change from baseline to study endpoint adopting mean differences (MD) in ng/mL as the effect size measure. The dose-response curves were estimated by conducting random-effects dose-response meta-analyses using the restricted cubic spline method.

RESULTS:

Among 165 eligible studies, 68 studies with 238 dose arms (23,128 participants, 35% female) reported on prolactin and were meta-analyzed. Of these, 94% lasted ≤ 3 months, and 90% of the studies used oral formulations. Participants in one study experienced their first episode, while all other studies also included multiepisode participants. The dose-response curves indicated that with aripiprazole, higher doses were significantly associated with lower prolactin levels than lower doses. Brexpiprazole, cariprazine, lumateperone, and quetiapine carried negligible risks for prolactin increase across examined doses. During treatment with most other antipsychotics, i.e., asenapine, haloperidol, iloperidone, lurasidone, olanzapine, paliperidone, risperidone, and ziprasidone, prolactin levels rose with increasing doses and then continued to increase or plateaued. The shape of the dose-response curves was similar in males and females, with generally larger amplitudes of the curves in females.

CONCLUSIONS:

The prolactin-increasing property varies among antipsychotics, is dose-related, and is greater in females. These findings in adults with acutely exacerbated schizophrenia can help clinicians titrate and adapt antipsychotic doses and consider patients' sex in treatment decisions. The protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO); registration no. CRD42020181467.

News (Medical) associated with Iloperidone

27 Feb 2026

·firstwordpharma.com

CHMP backs drugs from Novartis, Crinetics while Vanda gets a thumbs down

The EMA's drug advisory panel issued its latest basket of recommendations and rejections on Friday, throwing its support behind six drugs, whilst declining to back two treatments. The most notable nod went to Moderna for mCombriax (mRNA-1083), a combination mRNA vaccine designed to protect adults 50 years and older against both seasonal flu and COVID-19. The shot's support from European regulators comes shortly after the FDA initially declined to review a US application for the standalone flu portion of the jab — mRNA-1010 — before reversing course and promising a decision by August 5. With the positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) in-hand, Moderna is now awaiting a final marketing authorisation decision on mCombriax from the European Commission. Good news for Crinetics, NovartisJust five months after Crinetics Pharmaceuticals won US clearance for its once-daily oral acromegaly treatment, it now has CHMP backing for Palsonify (paltusotine) in the EU.The nonpeptide somatostatin receptor type 2 (SST2) agonist is supported by data from two Phase III pivotal trials, PATHFNDR-1 and PATHFNDR-2, which respectively enrolled previously treated and treatment-naïve adults with acromegaly, a rare hormonal disorder caused by the the production of excess growth hormone. In both studies, a significantly higher proportion of participants receiving Palsonify maintained IGF-1 levels ≤1 times the upper limit of normal compared with those on placebo, alongside significant reductions in acromegaly-associated symptoms.A FirstWord analysis pegged Crinetics as a likely takeout target this year, given its positive US launch of Palsonify (see – Vital Signs: The seller's marketplace heading into JPM).On a similar timeline as Crinetics, Novartis also bagged CHMP backing after a September FDA approval; the Swiss pharma got a positive recommendation for Rhapsido (remibrutinib) to treat chronic spontaneous urticaria (CSU).In the late-stage REMIX-1 and REMIX-2 studies, Rhapsido outperformed placebo on standard measures of itch, hive counts and overall disease activity at 12 weeks, with significantly more treated patients than placebo recipients reporting control of symptoms as early as the second week.In the US, the BTK inhibitor is indicated for adults who remain symptomatic despite taking antihistamines. As a twice-daily pill, it offers patients with CSU an oral alternative to existing injectable therapies.Nods for Ipsen, X4Also earning a thumbs up from CHMP was Ipsen and its paediatric brain cancer treatment, Ojemda (tovorafenib). The conditional marketing recommendation covers its use as monotherapy in patients aged 6 months and older with low-grade glioma harbouring a BRAF fusion or rearrangement or BRAF V600 mutation and who have progressed after one or more prior systemic therapies. Ipsen licensed the pan-RAF kinase inhibitor from Day One Biopharmaceuticals in 2024, after it received FDA approval in a similar setting. Rounding out the positive opinions was X4 Pharmaceuticals' Xolremdi (mavorixafor), which got a nod from CHMP "under exceptional circumstances" to treat patients aged 12 and up with WHIM syndrome, an ultra-rare immunodeficiency and chronic neutropenic disorder caused by CXCR4 pathway dysfunction; The disease is named for its four classic manifestations: warts, hypogammaglobulinaemia, infections and myelokathexis.Despite winning FDA approval in 2024 for the CXCR4 antagonist, X4 has struggled to remain afloat. The company in 2025 underwent two separate rounds of layoffs to stretch its cash runway to a topline readout of the Phase III 4WARD study evaluating Xolremdi in chronic neutropenia, expected next half. Negative opinions for Acadia, VandaOne of Friday's two rejections was not a surprise. Acadia Pharmaceuticals disclosed earlier this month that it expected to receive a negative opinion for trofinetide in Rett syndrome, a rare neurodevelopmental condition. Acadia has said it will seek a re-examination of its application for the IGF-1 analogue, which is already approved in the US and Canada under the brand name Daybue.The other thumbs-down, however, went to an atypical antipsychotic that has been cleared in the US to treat schizophrenia since 2009. More recently, Vanda Pharmaceutical's Fanapt (iloperidone) got a nod from the FDA in 2024 for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. In its rejection of iloperidone in both disease settings, CHMP wrote that the drug was associated with pronounced QT prolongation, "which is not outweighed by the benefits of treatment." Vanda may ask for re-examination of the opinion within 15 days.

Drug ApprovalPhase 3Clinical ResultVaccineImmunotherapy

25 Feb 2026

·www.prnewswire.com

Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation

Feb. 20, 2026 -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved BYSANTI™ (milsaperidone) tablets, a first line therapy for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for the treatment of schizophrenia in adults. BYSANTI™ is a new chemical entity (NCE) that belongs in the class of atypical antipsychotics. In clinical studies BYSANTI™ demonstrated bioequivalence to iloperidone across the therapeutic dosing spectrum enabling it to leverage well-established knowledge of efficacy and safety derived from a rich clinical development program and more than 100,000 patient-years of real-world experience with Fanapt® (iloperidone). As such BYSANTI™ represents a novel therapeutic option with a trusted safety profile in the treatment of these serious psychiatric conditions."The BYSANTI™ approval marks a significant step forward, offering patients and providers a reliable new treatment grounded in extensive clinical heritage," said Mihael H. Polymeropoulos, M.D., President, CEO and Chairman of the Board of Vanda Pharmaceuticals. "BYSANTI™ exemplifies a new era of accelerated innovation in drug development that can transform how we address unmet needs in behavioral health." BYSANTI™ is currently being tested as a once-daily adjunctive treatment in treatment-resistant major depressive disorder in an ongoing clinical study expected to complete by the end of this year. BYSANTI™ (milsaperidone), a new chemical entity, rapidly interconverts to iloperidone, providing dual active molecules that work in tandem by antagonizing dopamine D2, serotonin 5-HT2A, and alpha1-adrenergic receptors to modulate key pathways in these disorders. Its safety profile aligns closely with that established for iloperidone. BYSANTI™'s unique in-class receptor binding profile, featuring strong alpha-adrenergic binding in excess of dopamine and serotonin receptor binding, makes it suitable for further investigation in conditions that include symptoms of hostility, agitation, and hyperarousal. Vanda anticipates commercial availability of BYSANTI™ in Q3 of 2026. BYSANTI™ marketing exclusivity is expected to be protected by regulatory data exclusivity and issued US patents, with the latest expiring in 2044, providing a robust foundation for long-term innovation and patient benefit. BYSANTI™ is the second new drug approval for Vanda in less than 2 months following the approval of NEREUS™ in December of 2025. Bipolar I disorder impacts a significant portion of the roughly 10 million Americans with bipolar disorder, characterized by manic or mixed episodes that require effective symptom management to enhance outcomes.1 Schizophrenia affects approximately 1% of the U.S. adult population (about 2.8 million people), often causing substantial functional impairment, frequent hospitalizations, and diminished quality of life.2345 References Harvard Medical School, 2007. National Comorbidity Survey (NSC). (2017, August 21). Potkin SG, et al. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. J Clin Psychopharmacol. 2008;28(2 Suppl 1):S4-S11. doi:10.1097/JCP.0b013e3181692787. Cutler AJ, et al. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol. 2008;28(2 Suppl 1):S20-S28. doi:10.1097/JCP.0b013e318169278d. Weiden PJ, et al. A Randomized Trial of Iloperidone for Prevention of Relapse in Schizophrenia: The REPRIEVE Study. J Clin Psychopharmacol. 2016;36(4):302-308. doi:10.1097/JCP.0000000000000516. (PMC4982888). Torres R, et al. Efficacy and Safety of Iloperidone in Bipolar Mania: A Double-Blind, Placebo-Controlled Study. J Clin Psychiatry. 2024;85(1):23m14966. doi:10.4088/JCP.23m14966. The content above comes from the network. if any infringement, please contact us to modify

Drug Approval

24 Feb 2026

·www.biopharmadive.com

Novo to cut GLP-1 drug prices; Palvella soars on study data

Today, a brief rundown of news from Novo Nordisk and Palvella Therapeutics, as well as updates from Gossamer Bio, Vanda Pharmaceuticals and Pfizer that you may have missed.Novo Nordisk on Tuesday announced plans to lower the U.S. list prices of its diabetes and obesity drugs by as much as 50% starting next year. According to Novo, Wegovy and Ozempics wholesale acquisition cost will be $675 per month effective Jan. 1, 2027 reductions of 50% and 35%, respectively, from their current prices. The cuts apply to all doses and also include Rybelsus, an oral medication Novo sells for diabetes. They dont affect the costs involved when people bypass insurance and pay for Novos drugs in cash. Ben FidlerShares of Palvella Therapeutics climbed by nearly 40% Tuesday on positive Phase 3 study results in people with vascular abnormalities known as microcystic lymphatic malformations. Palvella said treatment with its therapy, a type of topical rapamycin gel, hit all main and key secondary goals and will be submitted to U.S. regulators this year. The data could position Palvellas drug as the first approved for the condition, and easily tops most expectations, wrote Mizuho Securities analyst Graig Suvannavejh. The findings also suggest the therapy could be viable in treating other vascular malformations, leaving significant value still waiting to be unlocked, he added. Ben FidlerSan Diego-based drugmaker Gossamer Bio lost more than 80% of its market value Monday after disclosing its sole clinical program failed a late-stage study. Gossamer, in collaboration with Chiesi Group, has been developing an experimental medicine called seralutinib across a couple lung diseases. Fresh results from a study focused on pulmonary arterial hypertension showed that, statistically, the medicine was not significantly better than a placebo on a test that evaluates lung capacity and cardiovascular health. Faheem Hasnain, Gossamers CEO, noted that this measure was narrowly missed, and the overall data clearly demonstrate seralutinib is an active drug in patients with PAH. The company therefore believes further discussions with the Food and Drug Administration regarding a potential path forward are warranted. Jacob BellThe FDA late last week approved a new atypical antipsychotic from Vanda Pharmaceuticals. Now sold as Bysanti, the medication works by inhibiting certain receptor proteins that interact with neurotransmitters like serotonin, dopamine and adrenaline. In the body, Bysanti breaks down into a molecule known as iloperidone, which is also the active ingredient in Vandas already marketed therapy Fanapt. The FDA specifically approved the newer product for schizophrenia and for the acute treatment of manic or mixed episodes associated with bipolar I disorder. Vanda said it expects Bysanti to become commercially available sometime between July and the end of September. Jacob BellPfizer will pay as much as $495 million for partial ownership of an injectable obesity medicine developed by Hangzhou, China-based Sciwind Biosciences. The deal announced Wednesday hands Pfizer exclusive commercialization rights in China to the therapy, which is known as ecnoglutide and already approved in the country for Type 2 diabetes. An approval application for weight management has also been accepted by Chinas drug regulator. Pfizer has been using dealmaking to acquire obesity assets. Last year, it paid $10 billion to nab Metsera and inked a potentially $2 billion licensing deal with YaoPharma. Ben Fidler '

Phase 3Drug ApprovalLicense out/inAcquisitionClinical Result

100 Deals associated with Iloperidone

External Link

KEGG	Wiki	ATC	Drug Bank
D02666	Iloperidone	N05AX14	DB04946

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Bipolar I disorder	United States	Vanda Pharmaceuticals, Inc.	02 Apr 2024
Mania	United States	Vanda Pharmaceuticals, Inc.	02 Apr 2024
Schizophrenia	United States	Vanda Pharmaceuticals, Inc.	06 May 2009

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute schizophrenia	Phase 3	United States	Vanda Pharmaceuticals, Inc.	18 Nov 2005
Acute schizophrenia	Phase 3	India	Vanda Pharmaceuticals, Inc.	18 Nov 2005
Osteoarthropathy, Primary Hypertrophic	Phase 2	United States	Vanda Pharmaceuticals, Inc.	01 Jun 2022
Parkinson Disease	Phase 2	United States	Vanda Pharmaceuticals, Inc.	01 Jun 2022
Irritable Mood	Phase 2	United States	Novartis Pharmaceuticals Corp.	01 Jul 2013
Sleep Initiation and Maintenance Disorders	Phase 2	United States	Novartis Pharmaceuticals Corp.	01 Jul 2013
Stress Disorders, Post-Traumatic	Phase 2	United States	Novartis Pharmaceuticals Corp.	01 Jul 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00254202 (CTgov)	Phase 3	Acute schizophrenia	593	Iloperidone (Iloperidone)	qtulrmqbqr(ntobkdfooc) = pchyyeoxso xkooamiskv (gqkouwpwpm, 1.03) View more	-	13 Dec 2024
				Ziprasidone (Ziprasidone)	qtulrmqbqr(ntobkdfooc) = hzzuhtklgl xkooamiskv (gqkouwpwpm, 1.44) View more
NCT04819776 (CTgov)	Phase 3	Mania \| Bipolar I disorder	417	Iloperidone (Iloperidone)	bihotnivou(lvlfmetkla) = giujnrjmez bkwgztbsde (iglcktltxd, 0.64) View more	-	16 Apr 2024
				Iloperidone Placebo (Placebo)	bihotnivou(lvlfmetkla) = evdgccycmj bkwgztbsde (iglcktltxd, 0.63) View more
NCT01291511 (REPRIEVE, CTgov)	Phase 3	Schizophrenia	635	Iloperidone (Iloperidone)	dayjwqdfih(rryvmgypdd) = rfvahnlebz fxkeqgdxvt (furwotwkfn, gpniepkred - zrqlztcazt) View more	-	17 Jul 2023
				Placebo (Placebo)	dayjwqdfih(rryvmgypdd) = zokaoknumd fxkeqgdxvt (furwotwkfn, ijjppsclms - nbbxegcghs) View more
NCT01917318 (CTgov)	Phase 2	Sleep Initiation and Maintenance Disorders \| Stress Disorders, Post-Traumatic \| Irritable Mood	1	Placebo+Iloperidone (Iloperidone / Placebo)	uyqqutovwm(nfdmdyqcnu) = vfccloweiy tchbsywhzw (zmaznsbmpm, qxrqayfdyn - tatueiufap) View more	-	31 Jan 2020
				Placebo+Iloperidone (Placebo / Iloperidone)	vxrmmjtehd = umvfxbncxs qivvyivivf (rrwefmllfo, hvinegfdvr - kgdmntotez) View more
NCT01920802 (CTgov)	Phase 4	-	31	olanzapine (Olanzapine)	bhteimcaet(evtbqomwnr) = owugpcuogg nruxvbbbvg (ubrkidnqul, 1.0) View more	-	20 Mar 2017
				iloperidone (Iloperidone)	bhteimcaet(evtbqomwnr) = thvqyflttz nruxvbbbvg (ubrkidnqul, 0.7) View more
NCT01291511 (REPRIEVE, Pubmed \| CNS Drugs) Manual	Phase 3	Schizophrenia	303	Iloperidone	kpwwywsbuh(dnpzgvsmtq) = nibqveduvg rpwtcrvawl (nslypljpri ) View more	Positive	01 Aug 2016
				Placebo	kpwwywsbuh(dnpzgvsmtq) = atrmsnblto rpwtcrvawl (nslypljpri ) View more
NCT01929889 (CTgov)	Phase 4	Schizoaffective disorder \| Schizophrenia	19	Iloperidone	tavnbsnuli(urfcbbxdln) = jmazadegle beukvrtfsh (dpfpdwzkmb, 3.742) View more	-	10 Jul 2015
NCT01207414 (i-FANS, CTgov)	Phase 4	Schizophrenia	501	iloperidone (Iloperidone Gradual Switch)	wvswleawwe(fyyfdztqic) = cfiouuayby armfyemgzq (sjwxhjmlgt, 1.1244) View more	-	15 Mar 2013
				iloperidone (Iloperidone Immediate Switch)	wvswleawwe(fyyfdztqic) = unkawnistn armfyemgzq (sjwxhjmlgt, 1.3300) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis